Obesity Management

With GLP-1 questions creating confusion for Medicare patients, pharmacists are becoming the trusted frontline resource, and the stakes for getting it right have never been higher.

New research links a national surge in poison control calls involving semaglutide to preventable dosing mistakes rather than intentional misuse.

With the goal of optimizing long-term weight-loss treatment, researchers gather insights regarding the lived experiences of glucagon-like peptide-1 users.

A new analysis shows that socioeconomic status shrinks type 2 diabetes risk far more for nonHispanic white and Asian Americans than for nonHispanic Black and Hispanic Americans.

Through a secret shopper study, researchers assessed the process for obtaining GLP-1 therapy via the internet and the clinical engagement associated with the purchase.

Data show bone density and lean mass losses can be clinically meaningful, but case reports point to resistance training as effective countermeasures.

The filing acceptance marks a step toward lower-cost alternatives to Mounjaro and Zepbound.

Bryan Wheeler, PharmD, discusses how the Medicare GLP-1 Bridge program works and what it means for independent pharmacy operations.

The FDA approved Foundayo, which is an oral glucagon-like peptide-1 receptor agonist, for weight loss.

Despite the boom in prescription weight loss medications, the management of OTC alternatives is still paramount in improving patient outcomes and reducing adverse events.

Reports state that everyone from “shadowy online vendors” to physicians and nurses is illegally promoting the drug before it receives proper FDA approval.

Based on data from the ADA’s 2026 Scientific Sessions, glucagon-like peptide-1s are continuing to revolutionize the cardiometabolic disease landscape.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

Alabama bans research-grade peptides for patients amid FDA reviewing 12 peptides for compounding use.

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.

Recent research data assessed the potential use of GLP-1s for reducing the progression of total knee arthroplasty.

Late-phase trials show switching to daily oral orforglipron or lower-dose tirzepatide helps maintain weight loss, easing regain and boosting adherence.

Results of Eli Lilly’s investigational triple agonist were reported in the TRIUMPH-1 Phase 3 clinical trial.

New OASIS 4 data show early oral semaglutide responders hit 21.6% weight loss and improve mobility.

The FDA seeks to bar bulk compounding of semaglutide, tirzepatide, and liraglutide, spotlighting risks in online glucagon-like peptide-1 copies.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.

Following an FDA announcement on its deeper look into peptide restrictions, Christopher Shade, PhD, joined to provide insights on their functions for metabolic health and more.

Researchers find Reddit posts provides a look at the real-world adverse effects of glucagon-like peptide-1 receptor agonists.

The FDA’s Pharmacy Compounding Advisory Committee will meet in late July of 2026 to convene on peptides and their inclusion on the 503A Bulk Drug Substances List.